A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with
tiotropium HandiHaler 18 micrograms (mcg) daily compared to Combivent Metered Dose Inhaler
(MDI) Chlorofluorocarbon Inhalation Aerosol 2 actuations four times a day in Chronic
Obstructive Pulmonary Disease (COPD) patients currently prescribed Combivent® MDI.